First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
Szeto HH. Br J Pharmacol. 2014;171(8):2029–2050. View source ↗
This foundational review by Hazel Szeto summarizes the design rationale and mechanism of the Szeto-Schiller (SS) peptide family, with SS-31 (D-Arg-Dmt-Lys-Phe-NH2) characterized in detail. The alternating positive-charge / aromatic-residue motif drives a membrane-potential-independent accumulation in the inner mitochondrial membrane, where SS-31 binds selectively to cardiolipin through a combination of electrostatic and hydrophobic interactions. By associating with cardiolipin, SS-31 stabilizes the cytochrome c–cardiolipin complex, suppresses the peroxidase activity that cardiolipin can otherwise impart to cytochrome c under stress, and preserves the structure of mitochondrial cristae. Downstream, the review summarizes in vitro and animal-model data showing preserved electron transport chain assembly, restored ATP synthesis, and reduced reactive oxygen species under conditions of mitochondrial stress.
Mitochondria are the parts of a cell that generate energy. Their inner membrane contains a special fat called cardiolipin that holds the energy-generating machinery in the right shape. When mitochondria are stressed, cardiolipin can start damaging the very proteins it normally supports. SS-31 acts like a protective patch — it sticks to cardiolipin, keeps the energy machinery properly assembled, and reduces the damaging side reactions. This 2014 paper by Dr. Szeto, who originally designed the peptide, lays out how SS-31 works and why it was the first compound of its kind.
